Application of human sDR5 protein as medicine to treat virus hepatitis B

A viral hepatitis and therapeutic drug technology, applied in the application field of human sDR5 protein as a therapeutic drug for hepatitis B, to achieve the effect of reducing liver cell apoptosis, reducing liver cell damage and improving prognosis

Active Publication Date: 2006-11-15
SHENZHEN ZHONGKE AMSHENN MEDICINE CO LTD
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] According to the search and novelty search by authoritative organizations, the use of human sDR5 protein as a drug for the treatment of hepatitis B to reduce liver cell apoptosis and liver cell damage by blocking or blocking the effect of TRAIL has not been reported at home and abroad.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of human sDR5 protein as medicine to treat virus hepatitis B
  • Application of human sDR5 protein as medicine to treat virus hepatitis B
  • Application of human sDR5 protein as medicine to treat virus hepatitis B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1: Purification of human sDR5 protein

[0062] Conventional method to activate pGAPZ-containing α A-sDR5 and empty vector pGAPZ α A Pichia strain, and a large number of sDR5-containing Pichia strain GS115 strains (see: Song K, Chen Y, Goke R, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune infection and cell cycle progression. J Exp Med, 2000; 191(7): 1095-1104), take pGAPZ respectively α A-sDR5 and empty vector pGAPZ α A Transformation-positive yeast, cultured for 24 hours, took 3L of supernatant, centrifuged at low temperature and high speed in a Beckman centrifuge (4°C, 8000rpm, 15min), and passed through a hollow fiber ultrafilter (ultrafiltration membrane cut-off flow: 3kDa) Concentrate 20 times by ultrafiltration.

[0063] ProBond TM The affinity chromatography column was passed through 20mmol / L Na 3 PO 4 After equilibrating with 500mmol / L NaCl (pH 7.2-7.6) binding buffer, pass the above sample mi...

Embodiment 2

[0065] Example 2: Preparation of a mouse model of hepatitis B virus, using methods of cell biology and molecular biology, the following experiments were carried out: to study the effect of human sDR5 protein on the liver injury of mice with hepatitis B virus.

[0066] (1) Set up normal BALB / c mouse control group (normal saline control group), seven doses of human albumin control group, seven doses of human sDR5 protein control group, empty vector control group, hepatitis B virus The model group, the treatment group with Minon 24 hours before the establishment of the model, the treatment group with seven doses of human sDR5 protein 24 hours before the establishment of the model, the treatment group with seven doses of human sDR5 protein at the same time after the establishment of the model, refer to sDR5 in mice Dosage used in experimental arthritis [See: Song K, Chen Y, Goke R, et al.Tumor necrosisfactor-related apoptosis-inducing ligand(TRAIL) is an inhibitor of autoimmuneinfl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of human s DR5 protein in preparing the medicines for treating the viral hepatitis B, especially the acute severe viral hepatitis B, by protecting liver cells and preventing the wither of liver cells is disclosed.

Description

(1) Technical field [0001] The present invention relates to the use of human sDR5 (soluble death receptor 5, soluble DR5, sDR5 for short) protein, and in particular to the application of human sDR5 protein as a drug for treating hepatitis B, especially acute severe viral hepatitis. (2) Background technology [0002] Hepatitis B virus is a worldwide disease caused by hepatitis B virus (HBV). It is the most common in China, with a high incidence rate and a continuous high epidemic trend. It not only directly affects the health of the population, but also It endangers people's lives, seriously affects people's production, life, work and study, and causes incalculable direct and indirect economic losses. [0003] Among the infectious diseases notifiable in my country, the number and incidence of viral hepatitis B have been at the forefront for many years. In 2005, the country listed viral hepatitis B as the four major infectious diseases for prevention and control. On February ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P1/16A61P31/12
Inventor 孙汶生陈有海高立芬刘玉刚梁晓红
Owner SHENZHEN ZHONGKE AMSHENN MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap